Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Company Overview
Agile Therapeutics Inc. (AGRX) is a dedicated women's healthcare company committed to addressing the unique health needs of modern women. Specializing in advanced transdermal drug delivery and contraceptive innovation, the company has developed products that offer women a flexible alternative to daily contraceptive pills. By harnessing its proprietary Skinfusion® technology, Agile Therapeutics delivers a non-daily, once-weekly prescription contraceptive patch that provides ease of use and improved patient adherence.
Innovative Technology and Product Focus
Central to Agile Therapeutics’ approach is its commitment to transforming women’s healthcare through innovation. The company’s lead product, Twirla®, is a combined hormonal contraceptive patch formulated using state-of-the-art transdermal technology. This system is designed to support efficient drug delivery, optimize patch adhesion, and enhance wearability, ensuring that women have a reliable and convenient contraception option without the burden of daily medication regimens.
Operational Excellence and Market Position
Agile Therapeutics operates at the intersection of biotechnology and patient-centric healthcare solutions. The company’s business model is built around leveraging its proprietary technologies to develop products that directly address the healthcare needs of women. By focusing on a specific niche in the contraceptive market, Agile Therapeutics has positioned itself as a key player in advancing non-daily contraceptive methods. Its strategic focus on innovation, controlled operating expenses, and collaborative partnerships underscores its commitment to sustainability and growth within the competitive healthcare landscape.
Commitment to Quality and Patient-Centric Solutions
At its core, Agile Therapeutics is driven by an unyielding focus on quality and patient safety. The design and development of its products, including Twirla®, are underpinned by rigorous clinical research and regulatory review. The company continually refines its product offerings to ensure that women receive a safe, effective, and convenient contraceptive option that meets modern lifestyle needs while ensuring adherence to high standards of medical care.
Industry Relevance and Competitive Landscape
Operating within the broader biotechnology and pharmaceutical sectors, Agile Therapeutics distinguishes itself by targeting a specific need within women’s healthcare. In a market where patient convenience, adherence, and minimized regimen complexity are paramount, the company’s focus on non-daily delivery systems sets it apart from traditional daily pill-based contraceptives and longer-acting methods. Its innovative approach and distinct value proposition highlight its relevancy and expertise in the competitive landscape, offering investors a clear insight into its business model and operational strategy.
Frequently Asked Questions
- What is the core business of Agile Therapeutics Inc.?
Agile Therapeutics focuses on creating innovative, non-daily contraceptive solutions designed to address the unique health needs of modern women through advanced transdermal technology. - What makes Twirla® unique?
Twirla® is a once-weekly combined hormonal contraceptive patch that utilizes the proprietary Skinfusion® platform to optimize patch adhesion and provide a convenient alternative to daily pills. - How does Agile Therapeutics generate revenue?
The company’s revenue model is primarily centered on the development, manufacturing, and commercialization of its prescription contraceptive products, supported by strategic partnerships and controlled operating expenses. - What role does transdermal technology play in its products?
Transdermal technology is fundamental to Agile’s approach, enabling effective and controlled drug delivery through the skin, which enhances patient compliance and convenience. - How is the company positioned within the competitive pharmaceutical landscape?
Agile Therapeutics differentiates itself by focusing on patient-centric, non-daily contraceptive solutions that fill a gap in women’s healthcare, thereby securing a niche within the broader biotech and pharmaceutical sectors. - What are the key advantages of Agile’s business model?
The company’s model leverages proprietary technology for innovative product development, emphasizes operational efficiency, and builds strategic partnerships to enhance market reach and sustainability.
Agile Therapeutics (Nasdaq: AGRX) announced it will release its Q4 and FY 2022 financial results on March 22, 2023, after market close. A live conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update. This event is an important platform for investors to gain insights into the company's financial health and strategic direction.
Corium Pharma Solutions has appointed Suzanne Hinchcliffe as its new Chief People Officer, enhancing its leadership team alongside recent appointments of industry veterans including Mark Sirgo as CEO and Ernie De Paloantonio as CFO. With over 20 years in human resources, Hinchcliffe aims to improve talent management and HR operations.
Corium specializes in drug delivery technologies and partners with notable companies like Proctor & Gamble (NYSE: PG) and Agile Therapeutics (NASDAQ: AGRX). The leadership changes are positioned to support the company’s growth and operational strategy in 2023 and beyond.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced it received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement. The new deadline is August 14, 2023. If the common stock's bid price closes at or above $1.00 for ten consecutive business days before this date, compliance will be confirmed by Nasdaq. Previously, Agile was notified of non-compliance on August 15, 2022. If compliance is not achieved by the new deadline, the company may face delisting. The company continues to monitor its stock price and seeks to meet Nasdaq's requirements.
Corium Pharma Solutions, Inc. (CPSI) announced the appointment of Ernie De Paolantonio as Chief Financial Officer on February 15, 2023. With over 30 years of financial experience in the pharmaceutical industry, including roles at Journey Medical Corporation and BioDelivery Sciences, Ernie aims to drive long-term growth for CPSI. This leadership addition aligns with the company's strategy, following recent key appointments including Mark Sirgo as CEO. Corium specializes in drug delivery technologies, partnering with major firms like Proctor & Gamble (NYSE: PG) and Agile Therapeutics (NASDAQ: AGRX).
Corium Pharma Solutions has appointed Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer, enhancing its leadership team. These appointments follow the recent selection of Mark Sirgo as Chief Executive Officer. Ostrander, with over 30 years in pharmaceuticals, previously led business development at ApiJect Systems and BioDelivery Sciences. Vasisht, a technology expert with over 25 years' experience, contributed to multiple FDA-approved products during his tenure at BDSI. Corium specializes in drug delivery technologies and has partnerships with major companies like Procter & Gamble and Agile Therapeutics.
Agile Therapeutics (Nasdaq: AGRX) announces FDA approval for extended milestones in the Twirla® long-term safety study, using electronic health records and insurance claims for VTE and ATE risk comparison. Interim safety data is due by November 2029, with the final report in November 2035. Agile continues focusing on Twirla's commercialization while evaluating the AG200-15 Extended Regimen and progestin-only patch development. A recent publication indicates the 12-week regimen may provide similar hormonal exposure to the approved 28-day regimen. However, Agile remains cautious about significant pipeline investment in 2023, prioritizing capital efficiency.
Agile Therapeutics (Nasdaq: AGRX) announced a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock for each outstanding share of its common stock, to be distributed on February 7, 2023. Holders of the Series C Preferred Stock will have voting rights related to a proposed reverse stock split. Each share carries significant voting power, with 1,000,000 votes per full share. Any shares not present at the stockholder meeting will be redeemed automatically. The Series C Preferred Stock will not be transferable except in connection with common stock transfers. Further details will be provided in a Form 8-K filing.
Agile Therapeutics, Inc. (Nasdaq: AGRX) reported a significant boost in Twirla factory sales, estimating a 30% increase in Q4 2022, totaling approximately 42,200 cycles, and an annual surge of 232% from 2021 with 113,600 total cycles. For 2023, the company anticipates net revenue between $25-$30 million, focusing on retail and non-retail channels while managing operating expenses. CEO Al Altomari highlighted growth momentum and ongoing efforts to expand their women’s health product portfolio.
Agile Therapeutics, a women's healthcare company, will participate in the RHK Capital Disruptive Growth Conference in New York on December 5-6, 2022. CEO Al Altomari will present a corporate overview on December 5 at 3:20 p.m. ET. The conference will be accessible through a live webcast on the company's investor relations page, and a replay will be available for 30 days post-event. Agile Therapeutics focuses on providing innovative contraceptive options, highlighted by its product Twirla, a non-daily prescription contraceptive designed using proprietary Skinfusion technology.
Agile Therapeutics (Nasdaq: AGRX) reported a 43% increase in net revenue for Q3 2022, totaling $3.0 million, driven by a 361% growth in non-retail channel Twirla cycles. The demand for Twirla rose by 35% quarter-over-quarter, with a total of 28,541 cycles sold. Despite a net loss of $19.7 million, Agile expects continued growth in Q4 2022 and 2023. Management highlighted the collaboration with Afaxys and a new CTV marketing campaign as key strategies for enhancing Twirla's market presence and awareness.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics Inc.?
How does Twirla® differ from traditional contraceptives?
What is the significance of the Skinfusion® platform?
What market need does Agile Therapeutics address?
How is Agile positioned within the biotechnology sector?
What are the core elements of Agile’s business model?
